Insiders Updates
A Guide To The Risks Of Investing In Syndax Pharmaceuticals Inc (SNDX)
Syndax Pharmaceuticals Inc’s filing revealed that its Head of R&D, CMO Botwood Nicholas A.J. acquired Company’s shares for reported $0.11
Menu
Syndax Pharmaceuticals Inc’s filing revealed that its Head of R&D, CMO Botwood Nicholas A.J. acquired Company’s shares for reported $0.11
In a filing, Syndax Pharmaceuticals Inc revealed its Head of R&D, CMO Botwood Nicholas A.J. acquired Company’s shares for reported
Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its
Syndax Pharmaceuticals, Inc. (SNDX), a clinical-stage healthcare company that focuses on an HDAC inhibitor for tumors and specializes in cancer